Skip to main content

Table 3 Hypothesized access milestones for each intervention

From: Implementing new health interventions in developing countries: why do we lose a decade or more?

 

Regulatory approval

A) Coordinating group

B) Improved intervention

C) Financing commitment

D) Initial WHO recommendation

E) Comprehensive WHO recommendation

HepB

1982

1986

1996

2000

n/a

1992

Hib

1988

1998

1997

2000

1998

2006

RV

2006

2003

2008

2007

2007

2009

PC

2000

2003

2009

2007

n/a

2007

ITN

1991

1998

2001

2002

1995

2007

RDT

1995

2003

n/a

2002

2006

2010

ACT

1999

1999

2009

2002

2002

2006

  1. Legend.
  2. Data sources below relate to the column number for each intervention. Websites were accessed on April 14, 2011 unless otherwise indicated.
  3. Hepatitis B vaccine: Regulatory approval) [58]; A) [59]; B) Personal communication, Marie-Claude Dubois, April 11, 2011; C) [60]; D) n/a; E) [61].
  4. Haemophilus influenzae type b vaccine: Regulatory approval) [43]; A) [62]; B) Personal communication, Marie-Claude Dubois, April 11, 2011; C) [63]; D-E) [43].
  5. Rotavirus vaccine : Regulatory approval) [54]; A) [64]; B) [65]; C) [66]; D-E) [43].
  6. Pneumococcal conjugate vaccine: Regulatory approval) [43]; A) [64]; B) [67]; C) [66]; D) n/a; E) [43].
  7. Insecticide-treated mosquito net: Regulatory approval) [49]; A) [68]; B) [50]; C) [69]; D) [70]; E) [51].
  8. Rapid diagnostic test: Regulatory approval) [71]; A) [8, 72]; B) n/a; C) [69]; D) [73]; E) [72].
  9. Artemisinin-based combination therapy: Regulatory approval) [74]; A) [75]; B) [76, 77]; C) [69]; D) [74]; E) [78].